CHRS

Coherus Oncology, Inc. (CHRS) | Rumor.io

Coherus Oncology

CHRS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,105

Bullish sentiment (50-day avg)72%

Price to earnings ratio3.07

Market capitalization176.1M

Earnings per share-1.24

Dividend yield (TTM)—

Revenue (annual)42.2M

Net income (annual)168M

Social

What share of all stock conversation is about CHRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Sep 25

The management team at Coherus BioSciences, Inc. (CHRS) is positioning the company for a strategic deal, with a focus on delivering data-driven results in the oncology space.
The company's separation of legacy biosimilar assets from its oncology business, facilitated by a shareholder CVR, may be undervalued, with potential buyers able to acquire individual assets or license them to strategic buyers.
The combination of recent events, including the involvement of M&A heavyweight Tom Davidson and the direct clinical collaboration with J&J, suggests that Coherus may be following a deliberate roadmap to maximize deal optionality, with key data-driven events approaching that could unlock strategic partnerships or M&A opportunities.

Generated by AI

Sentiment

Of the messages about CHRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	73.79% +12.42	70.62% +14.39	75% -1.44
Bearish	—	26.21% -12.42	29.38% -14.39	25% +1.44

Bullish· May 11

Guggenheim initiated a Buy rating on CHRS with a $12 target price, citing the potential for big upside in the company's cancer drug pipeline.
CHS-114, a breakthrough drug candidate, is expected to be a game-changer in the CCR8 space, with a highly selective mechanism that targets only the bad cells and spares the good ones.
CHRS has shown technical signs of life, including a heating up RSI, a turning bullish MACD, and increasing volume, making a move towards the $2.50-$2.60 range a possibility.

Bearish· Aug 5

The company's CEO, Denny, is being criticized for his leadership and the company's poor performance over the past 5 years, with some calling for his removal.
The company's stock option re-pricing and compensation practices are being questioned, with some suggesting that the CEO is desperate to lose money or is internally aware that the company's performance will be poor.
The company's data release has been delayed, and some analysts are predicting that the stock will drop below $1, with others calling the company a "dud" and a "shit show" with no prospect of success until the CVR's expire in a few years.

Generated by AI

Topics

Of the messages about CHRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	94.51%	43.17%
Earnings	—	0%	0%	5.4%
Controversies	—	0%	0%	1.22%
Analysts	—	0%	0%	16.46%
Technical Analysis	—	0%	5.49%	25.77%
Macro	—	0%	0%	7.99%

Earnings· Nov 6

Coherus BioSciences, Inc. (CHRS) reported a 64% earnings increase YOY and plans to constrain and reduce expenses across the board.
The company's Q3 EPS was 41c, beating consensus of 31c, but Q3 revenue was $74.57M, missing consensus of $83.56M.
CHRS expects further revenue growth driven by CIMERLI, UDENYCA, YUSIMRY, and LOQTORZI, while holding the line on expenses and focusing on returning to profitability.

Analysts· Jun 13

Coherus BioSciences, Inc. ($CHRS) has received multiple price target updates and rating reiterations from various analysts, including buy ratings and price targets ranging from $38 to $45.
Credit Suisse Group has given $CHRS a $38 price target, while Cowen & Company reiterates an outperform rating with a $45 price target.
Analysts at BMO Capital Markets and Cowen & Company have also reiterated outperform ratings for $CHRS, with price targets of $43 and $45, respectively.

Announcements· Dec 5

Coherus BioSciences, Inc. (CHRS) has entered into an asset purchase agreement with Intas Pharmaceuticals for the divestiture of the UDENYCA franchise for up to $558.4 million.
The transaction includes an upfront payment of $483.4 million and up to $75 million in potential net sales milestone payments, which will be used to fully repay the company's $230 million in existing convertible notes.
The deal is expected to provide Coherus with a significant influx of cash, which will be used to further develop its pipeline of next-generation PD-1 drugs, including its FDA-approved LOQI TORZI IP.

Technical Analysis· Dec 3

The RSI for CHRS was previously at a similar level 5 years ago, when the stock price was $19.
A sustained intraday breakout over $2.40 or $2.50 would be appealing for scalping high-probability moves to the upside.
The stock has formed a bull pennant, with extension targets at $2.10, $2.50, or possibly $2.85+, and support at $1.55 or $1.65.

Generated by AI

Community

Of the messages about CHRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	36.36%	95.59%	89.74%	75.66%
Newcomers	63.64%	4.41%	10.26%	24.34%

Regulars· Sep 25

The regulars are focused on the potential for a buyout, with probabilities of 30-40% within 12 months and 50-60% if Casdo/Tagmo deliver strong data.
The sequence of events, including the Innovatus refinancing, Strategic Financing Transaction Committee, CVR, Leerink ATM, and Oppenheimer global bidding process, suggests a deliberate plan to separate legacy value from the oncology company and create a cleaner strategic entity.
The combination of J&J's clinical collaboration with Tagmo, the "Drugs, Data & Deals" strategy, and the expertise of Tom Davidson, Co-President of Leerink, creates a potential roadmap for Coherus, involving funding the company, separating legacy value, cleaning up oncology, generating data, and maximizing partnering/M&A optionality.

Newcomers· Jan 26

The stock price of CHRS is in a rebound channel and may be poised for a breakout if it stabilizes at $2.270 and breaks through $2.285 in volume.
CHRS has surged to $2.06, up 29.56%, driven by profit growth accelerating rapidly, and a major presentation at the J.P. Morgan Healthcare Conference providing the catalyst.
The quarterly results of CHRS have significantly outperformed Street estimates, and the stock is being driven by strategic presentation at the J.P. Morgan Healthcare Conference, with a high-conviction catalyst play.

Generated by AI

News

Coherus initiates sale of legacy biosimilars assets

6d agoInvesting.com

Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

Coherus Oncology (CHRS) said Wednesday it has begun the process to sell remaining assets related to

6d agoYahoo Finance

Coherus at Morgan Stanley healthcare conference: oncology push gains traction

13d agoInvesting.com

Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push

14d agoInvesting.com

Coherus to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.Morgan Stanley 24th Annual Global Healthcare Confere

29d agofinance.yahoo.com

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development

1mo agoSeeking Alpha

Also Discussed

Investors talking about CHRS also mention

#	Name	Attention
1	CKPT - Checkpoint Therapeutics, Inc.	——
2	SURF - Surface Oncology, Inc.	——
3	Arcutis Biotherapeutics, Inc.ARQT	0%+0
4	BLUE - bluebird bio, Inc.	——
5	Janux Therapeutics, Inc.JANX	0%0
6	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
7	DAWN - Day One Biopharmaceuticals, Inc.	——
8	SWTX - SpringWorks Therapeutics, Inc.	——
9	Alvotech SAALVO	0%new
10	GBIO - Generation Bio Co.	——

Coherus Oncology, Inc.

Healthcare
Biotechnology

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.

Website

Location

333 Twin Dolphin Drive

Redwood City, CA, 94065

United States

Social

What share of all stock conversation is about CHRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Sep 25

The management team at Coherus BioSciences, Inc. (CHRS) is positioning the company for a strategic deal, with a focus on delivering data-driven results in the oncology space.
The company's separation of legacy biosimilar assets from its oncology business, facilitated by a shareholder CVR, may be undervalued, with potential buyers able to acquire individual assets or license them to strategic buyers.
The combination of recent events, including the involvement of M&A heavyweight Tom Davidson and the direct clinical collaboration with J&J, suggests that Coherus may be following a deliberate roadmap to maximize deal optionality, with key data-driven events approaching that could unlock strategic partnerships or M&A opportunities.

Generated by AI

Sentiment

Of the messages about CHRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	73.79% +12.42	70.62% +14.39	75% -1.44
Bearish	—	26.21% -12.42	29.38% -14.39	25% +1.44

Bullish· May 11

Guggenheim initiated a Buy rating on CHRS with a $12 target price, citing the potential for big upside in the company's cancer drug pipeline.
CHS-114, a breakthrough drug candidate, is expected to be a game-changer in the CCR8 space, with a highly selective mechanism that targets only the bad cells and spares the good ones.
CHRS has shown technical signs of life, including a heating up RSI, a turning bullish MACD, and increasing volume, making a move towards the $2.50-$2.60 range a possibility.

Bearish· Aug 5

The company's CEO, Denny, is being criticized for his leadership and the company's poor performance over the past 5 years, with some calling for his removal.
The company's stock option re-pricing and compensation practices are being questioned, with some suggesting that the CEO is desperate to lose money or is internally aware that the company's performance will be poor.
The company's data release has been delayed, and some analysts are predicting that the stock will drop below $1, with others calling the company a "dud" and a "shit show" with no prospect of success until the CVR's expire in a few years.

Generated by AI

Topics

Of the messages about CHRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	94.51%	43.17%
Earnings	—	0%	0%	5.4%
Controversies	—	0%	0%	1.22%
Analysts	—	0%	0%	16.46%
Technical Analysis	—	0%	5.49%	25.77%
Macro	—	0%	0%	7.99%

Earnings· Nov 6

Coherus BioSciences, Inc. (CHRS) reported a 64% earnings increase YOY and plans to constrain and reduce expenses across the board.
The company's Q3 EPS was 41c, beating consensus of 31c, but Q3 revenue was $74.57M, missing consensus of $83.56M.
CHRS expects further revenue growth driven by CIMERLI, UDENYCA, YUSIMRY, and LOQTORZI, while holding the line on expenses and focusing on returning to profitability.

Analysts· Jun 13

Coherus BioSciences, Inc. ($CHRS) has received multiple price target updates and rating reiterations from various analysts, including buy ratings and price targets ranging from $38 to $45.
Credit Suisse Group has given $CHRS a $38 price target, while Cowen & Company reiterates an outperform rating with a $45 price target.
Analysts at BMO Capital Markets and Cowen & Company have also reiterated outperform ratings for $CHRS, with price targets of $43 and $45, respectively.

Announcements· Dec 5

Coherus BioSciences, Inc. (CHRS) has entered into an asset purchase agreement with Intas Pharmaceuticals for the divestiture of the UDENYCA franchise for up to $558.4 million.
The transaction includes an upfront payment of $483.4 million and up to $75 million in potential net sales milestone payments, which will be used to fully repay the company's $230 million in existing convertible notes.
The deal is expected to provide Coherus with a significant influx of cash, which will be used to further develop its pipeline of next-generation PD-1 drugs, including its FDA-approved LOQI TORZI IP.

Technical Analysis· Dec 3

The RSI for CHRS was previously at a similar level 5 years ago, when the stock price was $19.
A sustained intraday breakout over $2.40 or $2.50 would be appealing for scalping high-probability moves to the upside.
The stock has formed a bull pennant, with extension targets at $2.10, $2.50, or possibly $2.85+, and support at $1.55 or $1.65.

Generated by AI

Community

Of the messages about CHRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	36.36%	95.59%	89.74%	75.66%
Newcomers	63.64%	4.41%	10.26%	24.34%

Regulars· Sep 25

The regulars are focused on the potential for a buyout, with probabilities of 30-40% within 12 months and 50-60% if Casdo/Tagmo deliver strong data.
The sequence of events, including the Innovatus refinancing, Strategic Financing Transaction Committee, CVR, Leerink ATM, and Oppenheimer global bidding process, suggests a deliberate plan to separate legacy value from the oncology company and create a cleaner strategic entity.
The combination of J&J's clinical collaboration with Tagmo, the "Drugs, Data & Deals" strategy, and the expertise of Tom Davidson, Co-President of Leerink, creates a potential roadmap for Coherus, involving funding the company, separating legacy value, cleaning up oncology, generating data, and maximizing partnering/M&A optionality.

Newcomers· Jan 26

The stock price of CHRS is in a rebound channel and may be poised for a breakout if it stabilizes at $2.270 and breaks through $2.285 in volume.
CHRS has surged to $2.06, up 29.56%, driven by profit growth accelerating rapidly, and a major presentation at the J.P. Morgan Healthcare Conference providing the catalyst.
The quarterly results of CHRS have significantly outperformed Street estimates, and the stock is being driven by strategic presentation at the J.P. Morgan Healthcare Conference, with a high-conviction catalyst play.

Generated by AI

Coherus Oncology

Social

Sep 25

Bullish· May 11

Bearish· Aug 5

Earnings· Nov 6

Analysts· Jun 13

Announcements· Dec 5

Technical Analysis· Dec 3

Regulars· Sep 25

Newcomers· Jan 26

Coherus initiates sale of legacy biosimilars assets

Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

Coherus at Morgan Stanley healthcare conference: oncology push gains traction

Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push

Coherus to Participate in Upcoming Investor Conferences

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development

Also Discussed

Coherus Oncology, Inc.

Company Information

Location

Coherus initiates sale of legacy biosimilars assets

Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

Coherus at Morgan Stanley healthcare conference: oncology push gains traction

Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push

Coherus to Participate in Upcoming Investor Conferences

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development

Also Discussed

Social

Sep 25

Bullish· May 11

Bearish· Aug 5

Earnings· Nov 6

Analysts· Jun 13

Announcements· Dec 5

Technical Analysis· Dec 3

Regulars· Sep 25

Newcomers· Jan 26